Renovorx Inc (RNXT) - News Archive

RenovoRx Unveils Promising Pharmacokinetic Data Amidst Challenging Market Conditions RenovoRx, a life sciences company known for its targeted oncology therapies, has taken a notable step forward by presenting new human...

In an important development for cancer treatment, RenovoRx, Inc. (Nasdaq: RNXT) a pioneering life sciences firm announced the upcoming presentation of groundbreaking pre-clinical data at the Society of Surgical Oncology...

Revolutionizing Cancer Care: RenovoRx s Expanding Intellectual Property Portfolio and Innovative Drug-Delivery Solutions In a rapidly evolving landscape of oncology treatments, RenovoRx, Inc. (Nasdaq: RNXT) stands at th...

In the ever-evolving landscape of oncology therapeutics, RenovoRx, Inc. stands at the forefront with its groundbreaking drug-delivery therapy platform, RenovoCath. The Mountain View-based life sciences company is not on...

RenovoRx Inc. has recently made significant strides in the clinical landscape of oncology with the initiation of patient enrollment in its pivotal Phase III clinical trial, TIGeR-PaC, aimed at evaluating the Trans-Arter...

The fight against cancer continues to gain momentum as RenovoRx Inc. embarks on an ambitious phase III clinical trial, known as the TIGeR-PaC study, aimed at evaluating its innovative therapeutic approach. With a commit...

In a positive development for RenovoRx Inc. the company has announced a significant increase in the production of its FDA-cleared RenovoCath delivery system. This decision comes in response to heightened demand from phy...

In the realm of oncology, delivering effective treatment modalities for challenging malignancies such as Locally Advanced Pancreatic Cancer (LAPC) remains an arduous task. RenovoRx has recently published promising early...

RenovoRx, an emerging pioneer in the realm of targeted cancer therapies, has recently announced a significant milestone: their latest data on the use of the RenovoCath™ system and targeted therapy platform for the treat...

Pancreatic cancer is one of the deadliest types of cancer, with a notably low survival rate. However, recent advancements in medical research have brought a beacon of hope to patients and healthcare professionals alike....

RenovoRx Appoints Ryan Witt as Senior Vice President to Drive Clinical and Commercial Business Development OpportunitiesRenovoRx, a pioneering healthcare technology company, announced the appointment of Ryan Witt as Sen...

RenovoRx, an innovative therapeutic technology company, has made a strategic move in appointing Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships. This newly created role signifies RenovoRx...

RenovoRx CEO Updates Shareholders on Significant Q1 Milestones LOS ALTOS, Calif. - RenovoRx, Inc. (Nasdaq: RNXT), a clinical-stage biopharmaceutical company specializing in the development of novel precision oncology th...

RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024RenovoRx, a prominent biopharmaceutical company known for its groundbreaking precision oncology therapies, has announced that...